Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. Read more about Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. Read more about Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). Read more about The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
The potential value of monitoring bone turnover markers among women on alendronate. Read more about The potential value of monitoring bone turnover markers among women on alendronate.
Rapidly increasing rates of hip fracture in Beijing, China. Read more about Rapidly increasing rates of hip fracture in Beijing, China.
Height loss in older women: risk of hip fracture and mortality independent of vertebral fractures. Read more about Height loss in older women: risk of hip fracture and mortality independent of vertebral fractures.
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. Read more about Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis.
Skeletal unloading-induced insulin-like growth factor 1 (IGF-1) nonresponsiveness is not shared by platelet-derived growth factor: the selective role of integrins in IGF-1 signaling. Read more about Skeletal unloading-induced insulin-like growth factor 1 (IGF-1) nonresponsiveness is not shared by platelet-derived growth factor: the selective role of integrins in IGF-1 signaling.
Osteoblast extracellular Ca2+ -sensing receptor regulates bone development, mineralization, and turnover. Read more about Osteoblast extracellular Ca2+ -sensing receptor regulates bone development, mineralization, and turnover.
Effects of antiresorptive treatment on nonvertebral fracture outcomes. Read more about Effects of antiresorptive treatment on nonvertebral fracture outcomes.
